[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

721.P1.62 Clinical Care - Transplantation Regimen Toxicities and Engraftment: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 4, 2010: 5:30 PM-7:30 PM
Hall A3/A4 (Orange County Convention Center)
Safety and Feasibility of Posaconazole as Oral Antifungal Prophylaxis In Pediatric Patients Under 12 Years of Age Following Allogeneic Stem Cell Transplantation

Michaela Döring, MD1*, Carsten Müller, MD2*, Astrid Kimmig, MD3*, Carl-Philipp Schwarze, MD3*, Peter Lang, MD4, Rupert Handgretinger, MD1 and Ingo Müller, MD5*

1Hematology/Oncology, Children's University Hospital, Tubingen, Germany
2Department of Pharmacology, University of Cologne
3Department of General Pediatrics, Hematology and Oncology, University Children`s Hospital, Tübingen, Germany
4Hematology / Oncology, University Children's Hospital, Tuebingen, Germany
5Clinic for Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Poster Board Number: I-288
Brain Natriuretic Peptide (BNP) Elevations In Allogeneic Stem Cell Transplant (ASCT) Recipients at the Time of WBC Engraftment. Correlation with Engraftment Syndrome and Cardiac Dysfunction

Iris Isufi1*, Amy Barile1*, Kerry Russell2*, Kasia Hryniewicz2*, Julie Baker1*, Erin Medoff1*, Daniel Jacoby2*, Forrester Lee2*, Francine M Foss1, Dennis L. Cooper, MD1 and Stuart Seropian1

1Hematologic Malignancies, Yale University School of Medicine, New Haven, CT
2Internal Medicine, Cardiology, Yale University School of Medicine, New Haven, CT

Poster Board Number: I-289
25-OH Vitamin D Deficiency Following Pediatric Hematopoietic Stem Cell Transplant

Christine Duncan, MD, MMSc1, Erin Apfelbaum, RN1*, Katherine Whitley1*, Steven P. Margossian, MD, PhD2 and Leslie E. Lehmann, MD3

1Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
2Pediatric Hem./Onc., Children's Hosp. Boston/DFCI, Boston, MA
3Pediatric Oncology-HSCT, Dana-Farber Cancer Institute, Boston, MA

Poster Board Number: I-290
Aprepitant (Emend®) Significantly Increases Sirolimus Levels In Patients Undergoing Allogeneic Hematopoietic Stem Cell transplantation 

Sepideh Shayani, Pharm.D.1*, Joycelynne Palmer, PhD2*, Tracey Stiller2*, Chan Holly, Pharm.D.1*, Svetlana Keuylian, Pharm.D.1*, Pablo Miguel Parker, M.D.3, Stephen Forman, MD3 and Ryotaro Nakamura, MD3

1Pharmacy, City of Hope National Medical Center, Duarte, CA
2Biostatistics, City of Hope National Medical Center, Duarte, CA
3Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

Poster Board Number: I-291
Primed-GCSF BMT Following Reduced Intensity Conditioning Regimen (RIC) for Patients (pts) with Poor-Prognosis, Heavily Pre-Treated, Hodgkin’s Disease (HD)

Rodolfo Calixto1*, Mauricio Ostronoff, MD2, Fabiana Ostronoff, MD3*, Djenane Manso3*, ANA Patricia Souto Maior2*, Alexandre Sucupira4*, Rodrigo Florencio, MD5*, Monique Martins2*, Luis Fabio Botelho1* and Mariana Coutinho1*

1BONE MARROW TRANSPLANTATION, REAL HOSPITAL PORTUGUES, Recife, Brazil
2BONE MARROW TRANSPLANTATION, Real Hosp. Portugues - Real TMO, Recife, Brazil
3BMT, Real Hospital Português - Real TMO, Recife, Brazil
4BMT, REAL HOSPITAL PORTUGUES, Recife
5Transplante de Medula Ossea, Real Hospital Portugues, Recife, Brazil

Poster Board Number: I-292
Primed-GCSF BMT After Reduced Intensity Conditioning (RIC) In Association with Rituximab for Patients (pts) with Refractory CD20+ Aggressive Lymphomas.

Rodolfo Calixto1*, Fabiana Ostronoff, MD2*, Mauricio Ostronoff, MD3, Alexandre Sucupira4*, Djenane Manso2*, ANA Patricia Souto Maior3*, Rodrigo Florencio, MD5*, Monique Martins3*, Luis Fabio Botelho1* and Mariana Coutinho1*

1BONE MARROW TRANSPLANTATION, REAL HOSPITAL PORTUGUES, Recife, Brazil
2BMT, Real Hospital Português - Real TMO, Recife, Brazil
3BONE MARROW TRANSPLANTATION, Real Hosp. Portugues - Real TMO, Recife, Brazil
4BMT, REAL HOSPITAL PORTUGUES, Recife
5Transplante de Medula Ossea, Real Hospital Portugues, Recife, Brazil

Poster Board Number: I-293
Does Bisphosphonate-Induced Osteonecrosis of the Jaw (BONJ) Preclude Intensive Chemotherapy? Oral and Infectious Toxicities Associated with Autotransplantation In Patients with BONJ

Prakash Varadarajan, MD1, Juan Toro2*, Robert M. Craig2*, Deanna Schneider3*, Ju-Hsien Chao2*, David Haile1* and Cesar O. Freytes, MD4

1University of Texas Health Science Center at San Antonio, San Antonio, TX
2Audie L. Murphy Memorial Veterans Hospital, San Antonio
3Audie L. Murphy Memorial Veterans Hospital, San Antonio, TX
4South Texas Veterans Health Care System, University of Texas Health Science Center at San Antonio, San Antonio, TX

Poster Board Number: I-294
Prognostic Factors on Survival After Hematopoietic Stem Cell Transplantation for Adult Over 40 Years In Aplastic Anemia

Hawk Kim1, Jae-Yong Kwak2, Byung Soo Kim3*, Sung Hyun Kim4, Sung-Hwa Bae, MD5, Sang Kyun Sohn6, Ho-Jin Shin7, Jong-Ho Won, MD, PhD8, Sung-Soo Yoon, MD, PhD9, Deog-Yeon Jo, MD, PhD10, Young-Don Joo11*, Jung Hye Choi12*, Myung Soo Hyun13* and Kyoo Hyung Lee14

1Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
2Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, South Korea
3Korea University Anam Hospital, Seoul, South Korea
4Div of Hem.-Onc., Dep of Internal Med., Dong-A University Hospital, Busan, South Korea
5Dept. of Int. Med., Daegu Catholic Univ. Hosp., Daegu, South Korea
6Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea
7Hematology, Pusan National University Hospital, Busan, South Korea
8College of Medicine Div. of Hem./Onc., Dept. of Med.", Soon Chun Hyang Univ. Hosp., Seoul, South Korea
9Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
10Department of Hematology/Oncology, Chungnam National University Hospital, Daejeon, South Korea
11Dept. of Internal Med./Hem., Inje Univ. Busan Baik-Hospital, Busan, South Korea
12Department of Internal Medicine, Hanyang University Kuri Hospital, Kuri-si, South Korea
13Department of Internal Medicine, Yeungnam University Medical Center, Daegu
14Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, South Korea

Poster Board Number: I-295
Use of RIC-Allosct In Patients Younger Than 45 Years Old Affected by MDS and Leukemia: A Monocenter Retrospective Analysis

Roberto Crocchiolo Jr.1*, Luca Castagna, MD2*, Sabine Furst, MD3*, Jean El Cheikh, MD, PhD1*, Catherine Faucher, MD4*, Raynier Devilliers1*, Alberto Vazquez5*, Nawel Belmecheri1*, Angela Granata4*, Evelyne D'Incan, M.D.1*, Norbert Vey, MD6 and Didier Blaise, MD1

1Hematology, Institut Paoli-Calmettes, Marseille, France
2ISTITUTO CLINICO HUMANITAS, Marseille, France
3Institut Paoli Calmettes, Marseille, France
4Institut Paoli-Calmettes, Marseille, France
5Hematology, Hopital Maciel, Montevideo, Uruguay
6Hopital Paoli-Calmettes, Marseille, France

Poster Board Number: I-296
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy In Adults with Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation

Adam Giermasz, MD, PhD1, Lloyd E. Damon, MD1, Lawrence D Kaplan, MD1, Willis H. Navarro, MD2, Kristen Hege, MD1*, Charles Linker, MD1 and Thomas Martin, MD1*

1Hematology Oncology, University of California-San Francisco, San Francisco, CA
2NMDP, Minneapolis, MN

Poster Board Number: I-297
Cyclophosphamide and Prednisone Induction Effectively Decreased the Incidence of Engraftment Syndrome In Patients with POEMS Syndrome Who Undergo Stem Cell Transplantation

Victor H Jimenez-Zepeda, MD, PD1, Donna E. Reece, MD, FRCPC2, Suzanne Trudel, MD, MSC, FRCPC3, Christine Chen, MD4, Ahmed M. Rabea, MD5 and Vishal Kukreti, MD, FRCPC6

1DMOH, Princess Margaret Hospital, Toronto, Ontario, ON, Canada
2Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
3McLaughlin Centre for Molecular Medicine, Princess Margaret Hospital, Toronto, ON, Canada
4Hem. and Medical Onc., Princess Margaret Hospital, Toronto, ON, Canada
5Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
6Div. of Hematology/Oncology, Princess Margaret Hospital, Toronto, ON, Canada

Poster Board Number: I-298
Pre-Transplant Rituximab Is Associated with Reduced Rate of Acute GvHD After RIC-Allosct In Lymphoma Patients: Results From A Retrospective Monocenter Analysis 

Roberto Crocchiolo Jr.1*, Jean El Cheikh, MD, PhD1*, Luca Castagna, MD2*, Alix Helvig1*, Sabine Furst, MD3*, Catherine Faucher, MD4*, Alberto Vazquez5*, Nawel Belmecheri1*, Angela Granata4*, Diane Coso, MD1*, Reda Bouadaballah1* and Didier Blaise, MD1

1Hematology, Institut Paoli-Calmettes, Marseille, France
2ISTITUTO CLINICO HUMANITAS, Marseille, France
3Institut Paoli Calmettes, Marseille, France
4Institut Paoli-Calmettes, Marseille, France
5Hematology, Hopital Maciel, Montevideo, Uruguay

Poster Board Number: I-299
Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit Thymoglobulin

Didier Blaise, MD1, Mohamad Mohty2, Jean Marie Boher, PhD3*, Noel Milpied, MD4, Nathalie Fegueux, MD5*, Anne Sirvent, MD6*, Sabine Furst, MD3*, Mauricette Michallet7, Jean El Cheikh, MD, PhD1*, Luca Castagna, MD8*, Patrice Chevallier9*, Jacques-Olivier Bay, MD, PhD10, Jean-Yves Cahn, MD11, Thierry Guillaume12*, Reda Bouabdallah, MD13*, Norbert Vey1*, Reza Tabrizi, MD4*, Christian Chabannon, MD, PhD3 and Catherine Faucher, MD14*

1Hematology, Institut Paoli-Calmettes, Marseille, France
2Hematology department, CHU de Nantes, Nantes, France
3Institut Paoli Calmettes, Marseille, France
4Hematology, CHU Bordeaux, Pessac, France
5Hematology, Hôpital Lapeyronie, Montpellier, France
6Hematologie Clinique, Hopital de l'Archet I, Nice, France
7Hôpital Edouard Herriot, Lyon, France
8ISTITUTO CLINICO HUMANITAS, Marseille, France
9CHU Nantes, Université Nantes, Nantes, France
10Hematology, Clermont-Ferrand, France
11Onco-Hematologie, CHU-Grenoble, Grenoble, Cedex O9, France
12Hematology Department, CHU de Nantes, Nantes, France
13IPC, Marseille, France
14Institut Paoli-Calmettes, Marseille, France

Poster Board Number: I-300
T Cell Chimerism After T Cell Depleted Allogeneic Stem Cell Transplantation Is Influenced  by Immunological Factors Including the Conditioning Regimen, CMV Serostatus and GvHD and Does Significantly Bias Overall Chimerism Status

Jessica C. Harskamp, MD*, Pim L.J. van der Heiden, MD*, Esther H.M. van Egmond*, Sabrina A.J. Veld*, Hans L. Vos, PhD*, Constantijn J.M. Halkes, MD, PhD, J.H. Frederik Falkenburg, MD, PhD and Erik W.A. Marijt, MD, PhD

Dept. of Hematology, Leiden University Medical Center, Leiden, Netherlands

Poster Board Number: I-301
Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant

Manish Sharma, MD1, Rima M. Saliba, PhD2*, Muzaffar H. Qazilbash, MD3, Grace-Julia Okoroji4*, Uday R Popat, MD2, Marcos de Lima, MD5*, Richard Champlin6 and Chitra Hosing, MD7

1Bone Marrow Transplantation, Temple University, Philadelphia, PA
2Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3SCT/CT Unit 423, UT M.D. Anderson Cancer Ctr., Houston, TX
4Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX
5Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
6Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX
7Department of Stem Cell Transplantation and Cellular Therapy, M. D. Anderson Cancer Center, Houston, TX

Poster Board Number: I-302
Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome

John Koreth, MBBS, DPhil1, Melinda Biernacki, MD2*, Julie Aldridge, MS3*, Haesook T Kim, PhD3, Edwin P Alyea III, MD1, Philippe Armand, MD, PhD1, Corey Cutler, MD, MPH, FRCPC1, Vincent T Ho, MD1, Catherine J Wu, MD1, Joseph H. Antin, MD1 and Robert J Soiffer, MD1*

1Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
2Department of Medicine, Brown University, Providence, RI
3Division of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA

Poster Board Number: I-303
Intravenous Busulphan in Combination with ETOPOSIDE and MELPHALAN Used as Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Lymphomas: Evaluation of Toxicity and Efficacy

Despina Mallouri1*, Ioanna Sakellari2*, Ioannis Batsis2*, Varnavas Konstantinou1*, Panayotis Baliakas1*, Athanasios Antoniou1*, Chrisa Apostolou1*, Achilles Anagnostopoulos3 and Athanasios Fassas1*

1Hematology - BMT unit, G .Papanicolaou Hospital, Thessaloniki, Greece
2Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
3Hematology - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece

Poster Board Number: I-304
Low Day 30 Total Donor Chimerism After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Poorer Overall Survival In Myeloid but Not Lymphoid DisordersClinically Relevant Abstract

John Koreth, MBBS, DPhil1, Haesook T Kim, PhD2, Vincent T Ho, MD1, Corey Cutler, MD, MPH, FRCPC1, Philippe Armand, MD, PhD1, Robert J Soiffer, MD1*, Joseph H. Antin, MD1 and Edwin P Alyea III, MD1

1Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
2Division of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA

Poster Board Number: I-305
The HCT-Specific Comorbidity Index Fails to Predict Survival After Allogeneic HCT In High Risk AML Patients - A Single Center Experience

Nicole Birninger1*, Martin Bornhäuser2*, Martin Wermke, MD1*, Stefani Parmentier, MD3*, Brigitte Mohr4*, Christoph Röllig, MD5*, Uwe Platzbecker6, Gerhard Ehninger, MD7 and Johannes Schetelig8*

1Medical Clinic I, University hospital, Dresden, Germany
2Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
3Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
4Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
5Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I , Dresden, Germany
6Medical Clinic I, University Hospital, Dresden, Germany
7Dept. of Medicine I, Dresden University of Technology, Dresden, Germany
8Medical Clinic I, University hospital , Dresden, Germany

Poster Board Number: I-306
Treosulfan, Etoposide and Cyclophosphamide as Non TBI-Conditioning Regimen Followed by Allogeneic SCT for Acute Lymphoblastic Leukemia

Nicolaus Kröger1*, Matthias Stelljes2*, Martin Bornhäuser3*, Wolfgang A. Bethge4*, Renate Arnold5, Hans Martin6*, Christoph Schmid, M.D.7*, Karin Kolbe8*, Nicola Goekbuget, MD9, Dieter Hoelzer, MD10, Axel R. Zander, MD11 and Dietrich Beelen12*

1Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2University of Münster, Münster, Germany
3Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
4Medical Department, Hematology and Oncology, University of Tuebingen, Tuebingen, Germany
5Department of Hematology and Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany
6Medizinische Klinik II, Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Germany
72. Medizinische Klinik, Zentralklinikum Augsburg, Augsburg, Germany
8III. Medical Department, Hematology, Oncology and Pneumology, University Medical Center, Mainz, Germany
9Department of Medicine II, J.W. Goethe University Hospital Frankfurt, Frankfurt, Germany
10Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany
11Clinic for Stem Cell Transplantation, University Medical Center, Hamburg, Germany
12Clinic for bone marrow transplantation, University hospital, Essen, Germany

Poster Board Number: I-307
Dynamics of Chimerism In Regulatory T Lymphocytes (Treg; CD4+/CD25+) After Allogeneic Stem Cell Transplantation

Víctor Noriega1*, Carolina Martinez-Laperche1*, David Serrano1*, Gabriela Rodriguez-Macias2*, Mi Kwon2*, Jorge Gayoso2*, Pascual Balsalobre1*, Jose Luis Diez-Martin, Dr.3 and Ismael Buno1*

1Hospital General Universitario Gregorio Marañon, Hematology , Madrid, Spain
2Hematology, Hospital General Univ. Gregorio Marañon, Madrid, Spain
3Hematology, Hospital General Univ. Gregorio Marañon, Madrid, Spain

Poster Board Number: I-308
Successful Control of Preexistent Active Infection by Granulocyte Transfusions During Conditioning Induced Cytopenia In Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Stem Cell Transplant

P. Dayand Borge Jr., MD1*, Narda Theobald, MA2*, Rosamma DeCastro, NP2*, Harry L. Malech, MD2, Susan Leitman, MD3 and Elizabeth M. Kang, MD2

1Department of Transfusion Medicine, Clinical Centre, NIH, Bethesda, MD
2Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
3Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD

Poster Board Number: I-309
Veno-Occlusive Disease After Haematopoietic Stem Cell Transplantation for β Thalassaemia Major Is Predicted by the Severity of Hepatic Fibrosis and Ameliorated by Defibrotide

Prashant Hiwarkar1*, Farah O'Boyle2*, Leena Karnik3*, Helen New, FRCP, FRCPath4*, Richard Szydlo5*, Irene Roberts, MD6 and Josu de la Fuente, PhD, FRCP, FRCPath7

1Department of Paediatric Haematology, St. Mary's Hospital, London, United Kingdom
2Bone marrow transplantation, Imperial College NHS trust
3Department of paediatric haematology, Imperial College London, London
4Department of paediatric haematology, Imperial College London, London, United Kingdom
5Department of Hematology, Imperial College London, London, United Kingdom
6Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom
7Imperial College London, London, United Kingdom

Poster Board Number: I-310
Serum Ferritin and Cardiac/Liver Magnetic Resonance Imaging In Evaluating Iron Overload for Patients with Bone Marrow Failure Conditions Undergoing Non-Myeloablative HSCT

Victoria J Tindell, MBChB FRCPath1*, Victoria T Potter, MBBS, FRCPA, FRACP1*, Rachel Kesse-Adu, MD FRCPath1*, Laura Reiff-Zall1*, Aloysius Y Ho1, Ghulam J. Mufti, MD2, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA1, Judith C. W. Marsh, MD1 and ZiYi Lim, MD1*

1Department of Haematological Medicine, Kings College Hospital, London, United Kingdom
2Department of Haematological Medicine, King's College Hospital, London, United Kingdom

Poster Board Number: I-311
Chimerism Analysis Is Predictive of Relapse-Free Survival After Allogeneic Transplantation for MDS

Sanjay R. Mohan, MD1, Lisa Rybicki, MS2*, Matt Kalaycio, MD3, Ronald Sobecks, MD1, Brian J. Bolwell, MD1 and Edward A. Copelan, MD1

1Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Poster Board Number: I-312
Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Teresa Field, MD, PhD1, Janelle Perkins, PharmD1*, Taiga Nishihori, MD1, Joseph Pidala2*, Hugo F. Fernandez, MD3, Marcie Tomblyn, MD, MS4, Mohamed Kharfan-Dabaja, MD5*, Lia Perez, MD2, Rami S. Komrokji, MD6, Jeffrey E. Lancet, MD6, Jongphil Kim7*, Ernesto Ayala, MD2, Melissa Alsina, MD2, Jose-Leonel ochoa-Bayona, M.D.1*, Alan F. List8 and Claudio Anasetti, MD9

1Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL
2Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL
3Blood and Bone Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Instittute, Tampa, FL
4Dept. of Blood & Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
5Moffitt Cancer Center, Tampa
6Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
7Moffitt Cancer Center, Tampa, FL
8H. Lee Moffitt Cancer Center, Tampa, FL
9H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Poster Board Number: I-313
A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation  for Patients with Refractory leukemia 

Usama Gergis, MD1*, Ellen Ritchie, MD1*, Gail J. Roboz, MD2, Joseph M. Scandura, MD, PhD3, Sebastian Mayer, MD1*, Tomer M Mark, MD, MSc4, Tsiporah B. Shore, MD5, Usama Wissa, MD1* and Eric J Feldman, MD6

1Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY
2Weill Medical College of Cornell University, New York, NY
3Div. of Hematology-Oncology, Leukemia & Bone Marrow Failure Program, New York, NY
4Medicine, Divison of Hematology and Oncology, Weill Cornell Medical College, New York, NY
5Cornell Medical Center Hematology/Oncology, The New York Hospital, New York, NY
6Division of Hematology and Medical Oncology, Cornell Medical Center, New York, NY

Poster Board Number: I-314
Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study 

Delva Deauna-Limayo, MD1, Omar S. Aljitawi, MD2, Siddhartha Ganguly, MD2, Sunil Abhyankar, MD2*, Jo Wick3* and Joseph McGuirk, DO2

1Dept. of Hematological Malignancies, Nevada Cancer Institute, Las Vegas, NV
2Department of Hematology/Oncology, University of Kansas Medical Center, Kansas City, KS
3Center for Biostatistics and Advanced Informatics, University of Kansas Medical Center, Kansas City

Poster Board Number: I-315
Long-Term Results of a Fast Transplant Versus a Classical Conditioning Strategy for Allogeneic Stem Cell Transplantation of High Risk Acute Myeloid Leukemia (AML) Patients 

Ulrich Duenzinger1*, Hans Martin1*, Sabine Mousset1*, Salem Agip1*, Stefan A. Klein2, Hubert Serve, MD1 and Gesine Bug1*

1Department of Medicine, Hematology/Oncology, Goethe-University Frankfurt, Frankfurt, Germany
2III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

Poster Board Number: I-316
The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) and Survival After Extracorporeal Photopheresis, Pentostatin, and Reduced Dose Total Body Irradiation (TUFTs) Conditioning Prior to Allogeneic Stem Cell Transplantation (SCT)

Shahrukh Hashmi, MD, MPH1, Jamie L Oliva, MS, NP2*, Jane L. Liesveld, MD3, Gordon L. Phillips II, MD4, Diane Nichols3* and Michael W. Becker, MD3*

1Hematology and Oncology, University of Rochester Medical Center, Rochester, NY
2University of Rochester Medical Center, Rochester, NY
3Univ. of Rochester Med. Ctr., Rochester, NY
4Wilmot Cancer Center BMT Program, University of Rochester, Rochester, NY

Poster Board Number: I-317
T-Cell Depletion Is An Alternative Approach for Patients >/= 55 Years Undergoing Allogeneic Stem Cell Transplantation  as Curative Therapy for Hematologic Diseases

Erica Petrlik, MD1*, Hugo Castro-Malaspina, MD2*, Farid Boulad, MD3, Esperanza B Papadopoulos, MD4 and Ann A. Jakubowski, MD, PhD2

1Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
2Allogeneic Bone Marrow Transplant Service-Medicine , Memorial Sloan-Kettering Cancer Center, New York, NY
3Pediatric BMT Service, Memorial Sloan-Kettering Cancer Center, New York, NY
4Adult Allogeneic Bone Marrow Transplantation, Memorial Sloan-Kettering Cancer Center, New York, NY

Poster Board Number: I-318
CD34+ Cell Dose Is the Major Cell Dose Determinant of Myeloid Engraftment After Single Umbilical Cord Blood Transplantation (sUCBT) for Adult Patients with High-Risk Hematologic Malignancies

Jaime Sanz, MD1*, Pau Montesinos, MD1*, David Martinez2*, Ignacio Lorenzo1*, Javier Palau1*, Luis Larrea3*, Dolores Planelles3*, Guillermo Martin1*, Isidro Jarque1*, Javier De La Rubia4*, Federico Moscardo, MD5*, Jesus Martinez6*, Miguel Angel Sanz1* and Guillermo F Sanz, MD, PhD1

1Hospital Universitario La Fe, Valencia, Spain
2Hematology, University Hospital La Fe, Valencia, Spain
3Centro de Transfusiones de la Comunidad Valenciana, Valencia
4Department of Hematology, Hospital Universitario La Fe, Valencia, Spain
5Hematology Service, Hospital Universitario La Fe, Valencia, Spain
6Hematology Department, University Hospital La Fe, Valencia, Spain

Poster Board Number: I-319
Higher Non-Relapse Mortality with BuCyVP Compared to BuCy In Allogeneic Hematopoietic Stem Cell Transplant

Hien Duong, MD1, Brian J. Bolwell, MD2, Lisa Rybicki, MS3*, Matt Kalaycio, MD4, Steven Andresen, DO1*, Ronald Sobecks, MD1, Robert Dean, MD2, John William Sweetenham, MD, FRCP2, Shawnda Tench1* and Edward A. Copelan, MD2

1Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH
3Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
4Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Poster Board Number: I-320

*signifies non-member of ASH